BetterLife Pharma Inc. (BETR.CN)
CAD 0.11
(0.0%)
CAD 0.11
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 324.74 Thousand CAD | 334.58% |
| 2022 | 74.72 Thousand CAD | -93.57% |
| 2021 | 1.16 Million CAD | -13.1% |
| 2020 | 1.33 Million CAD | -83.8% |
| 2019 | 8.25 Million CAD | -4.01% |
| 2018 | 8.59 Million CAD | 1715.3% |
| 2017 | 473.52 Thousand CAD | 172.39% |
| 2016 | 173.84 Thousand CAD | 17.2% |
| 2015 | 148.32 Thousand CAD | 9112.61% |
| 2014 | 1610.00 CAD | -77.54% |
| 2013 | 7167.00 CAD | 18.33% |
| 2012 | 6057.00 CAD | 57.57% |
| 2011 | 3844.00 CAD | -77.75% |
| 2010 | 17.27 Thousand CAD | -8.98% |
| 2009 | 18.97 Thousand CAD | -36.15% |
| 2008 | 29.72 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 449.69 Thousand CAD | -43.26% |
| 2024 Q1 | 792.53 Thousand CAD | 144.05% |
| 2023 Q4 | 324.74 Thousand CAD | -36.26% |
| 2023 FY | 324.74 Thousand CAD | 334.58% |
| 2023 Q1 | 722.32 Thousand CAD | 866.62% |
| 2023 Q2 | 399.59 Thousand CAD | -44.68% |
| 2023 Q3 | 509.52 Thousand CAD | 27.51% |
| 2022 Q2 | 250.63 Thousand CAD | -30.26% |
| 2022 Q1 | 359.4 Thousand CAD | -69.05% |
| 2022 Q4 | 74.72 Thousand CAD | -73.23% |
| 2022 Q3 | 279.19 Thousand CAD | 11.39% |
| 2022 FY | 74.72 Thousand CAD | -93.57% |
| 2021 Q2 | 5.67 Million CAD | 296.06% |
| 2021 Q3 | 3.02 Million CAD | -46.66% |
| 2021 Q4 | 1.16 Million CAD | -61.65% |
| 2021 FY | 1.16 Million CAD | -13.1% |
| 2021 Q1 | 1.43 Million CAD | 7.28% |
| 2020 Q2 | 6.64 Million CAD | -2.12% |
| 2020 FY | 1.33 Million CAD | -83.8% |
| 2020 Q4 | 1.33 Million CAD | -89.56% |
| 2020 Q1 | 6.78 Million CAD | -17.73% |
| 2020 Q3 | 12.79 Million CAD | 92.62% |
| 2019 Q2 | 17.92 Million CAD | 87.76% |
| 2019 FY | 8.25 Million CAD | -4.01% |
| 2019 Q4 | 8.25 Million CAD | -48.55% |
| 2019 Q3 | 16.03 Million CAD | -10.56% |
| 2019 Q1 | 9.54 Million CAD | 11.09% |
| 2018 FY | 8.59 Million CAD | 1715.3% |
| 2018 Q4 | 8.59 Million CAD | -7.46% |
| 2018 Q2 | 9.88 Million CAD | -12.69% |
| 2018 Q1 | 11.32 Million CAD | 2290.99% |
| 2018 Q3 | 9.28 Million CAD | -6.04% |
| 2017 Q2 | 44.91 Thousand CAD | -50.43% |
| 2017 FY | 473.52 Thousand CAD | 172.39% |
| 2017 Q4 | 473.52 Thousand CAD | -31.03% |
| 2017 Q3 | 686.56 Thousand CAD | 1428.58% |
| 2017 Q1 | 90.61 Thousand CAD | -47.88% |
| 2016 Q3 | 306.79 Thousand CAD | 1231.52% |
| 2016 Q2 | 23.04 Thousand CAD | -66.58% |
| 2016 FY | 173.84 Thousand CAD | 17.2% |
| 2016 Q4 | 173.84 Thousand CAD | -43.34% |
| 2016 Q1 | 68.93 Thousand CAD | -53.52% |
| 2015 Q1 | 35.02 Thousand CAD | 2075.22% |
| 2015 FY | 148.32 Thousand CAD | 9112.61% |
| 2015 Q4 | 148.32 Thousand CAD | -28.75% |
| 2015 Q3 | 208.17 Thousand CAD | -23.42% |
| 2015 Q2 | 271.83 Thousand CAD | 676.19% |
| 2014 FY | 1610.00 CAD | -77.54% |
| 2014 Q4 | 1610.00 CAD | -79.62% |
| 2014 Q3 | 7901.00 CAD | -31.35% |
| 2014 Q2 | 11.5 Thousand CAD | 70.86% |
| 2014 Q1 | 6736.00 CAD | -6.01% |
| 2013 Q3 | 14.31 Thousand CAD | 110.0% |
| 2013 Q1 | 20.62 Thousand CAD | 240.48% |
| 2013 Q2 | 6818.00 CAD | -66.94% |
| 2013 FY | 7167.00 CAD | 18.33% |
| 2013 Q4 | 7167.00 CAD | -49.94% |
| 2012 Q2 | 6715.00 CAD | -6.01% |
| 2012 FY | 6057.00 CAD | 57.57% |
| 2012 Q4 | 6057.00 CAD | -8.53% |
| 2012 Q3 | 6622.00 CAD | -1.38% |
| 2012 Q1 | 7144.00 CAD | 85.85% |
| 2011 Q4 | 3844.00 CAD | -48.22% |
| 2011 Q3 | 7423.00 CAD | -64.52% |
| 2011 Q2 | 20.92 Thousand CAD | -65.51% |
| 2011 Q1 | 60.66 Thousand CAD | 251.15% |
| 2011 FY | 3844.00 CAD | -77.75% |
| 2010 FY | 17.27 Thousand CAD | -8.98% |
| 2010 Q2 | 2744.00 CAD | -55.73% |
| 2010 Q3 | 1900.00 CAD | -30.76% |
| 2010 Q4 | 17.27 Thousand CAD | 809.21% |
| 2010 Q1 | 6198.00 CAD | -67.34% |
| 2009 FY | 18.97 Thousand CAD | -36.15% |
| 2009 Q4 | 18.97 Thousand CAD | 0.0% |
| 2008 FY | 29.72 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 4.19 Million CAD | 92.256% |
| Asep Medical Holdings Inc | 25.61 Million CAD | 98.732% |
| BioVaxys Technology Corp. | 113.47 Thousand CAD | -186.175% |
| ChitogenX Inc. | 534 Thousand CAD | 39.186% |
| Rapid Dose Therapeutics Corp. | 1.88 Million CAD | 82.774% |
| Defence Therapeutics Inc. | 477.74 Thousand CAD | 32.026% |
| Entheon Biomedical Corp. | 401.07 Thousand CAD | 19.032% |
| Gemina Laboratories Ltd. | 1.45 Million CAD | 77.7% |
| Glow Lifetech Corp. | 1.91 Million CAD | 83.024% |
| Lexston Life Sciences Corp. | 750.94 Thousand CAD | 56.755% |
| Pharmala Biotech Holdings Inc. | 2.41 Million CAD | 86.539% |
| Doseology Sciences Inc. | 1.1 Million CAD | 70.537% |
| MYND Life Sciences Inc. | 797.54 Thousand CAD | 59.282% |
| Nova Mentis Life Science Corp. | 31.05 Thousand CAD | -945.578% |
| PharmaTher Holdings Ltd. | 2.58 Million CAD | 87.461% |
| PreveCeutical Medical Inc. | 181.51 Thousand CAD | -78.914% |
| Telescope Innovations Corp. | 3.02 Million CAD | 89.259% |